Clinical Trial Update: Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating the immunogenicity, efficacy, and safety of the Convacell vaccine in healthy adults aged 18 and older is ongoing; current …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Respiratory Infection
• Coronavirus Infections
• Respiratory Tract Infections

Drugs mentioned

• Convacell

Snippet

Sponsor: St. Petersburg Research Institute of Vaccines and Sera | Conditions: COVID-19, Coronavirus Infections | Phase 2, Phase 3 | Status: UNKNOWN